Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

Full Abstract

Lapatinib is an oral dual tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2), both frequently overexpressed in human cancer. Preclinical data have shown that lapatinib is a potent and selective inhibitor of the tyrosine kinase domain of EGFR and HER2, and tumor cells that overexpress these receptors are growth inhibited by lapatinib both in vitro and in vivo. Phase I clinical trials have shown that lapatinib is well tolerated, with mild diarrhea and rash the most frequent toxicities, and early evidence of clinical efficacy has been reported especially in HER2-positive breast cancer. Phase II studies have shown activity for lapatinib in trastuzumab-refractory breast cancer either alone or in combination with trastuzumab. When used as first-line monotherapy for advanced breast cancer, objective tumor responses have been seen in 28% of patients with untreated HER2-positive advanced breast cancer. An extensive phase III program in advanced breast cancer is now in progress both for refractory disease and as first-line therapy in combination with chemotherapy with and without trastuzumab, and with endocrine therapy. Phase II studies have also been conducted in a variety of other tumors, including renal cell cancer. Parallel biomarker studies are starting to elucidate predictive molecular phenotypes that may indicate likelihood of response to lapatinib, and these may direct future trials with this oral tyrosine kinase inhibitor.(c) 2006 Prous Science. All rights reserved.

Learn Faster Today Improve your study skills

Author information

Author/s: Johnston, Stephen R D (SR); Leary, Alex (A);

Affiliation: Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK. stephen.johnston(-atsign-)rmh.nhs.uk

Journal and publication information

Publication Type: Journal Article; Review

Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)), published in Spain. (Language: eng)

Reference: 2006-Jul; vol 42 (issue 7) : pp 441-53

Dates: Created 2006/08/08; Completed 2006/10/03; Revised 2007/11/15;

PMID: 16894399, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Neoplasms - drug therapy
Protein Kinase Inhibitors - chemistry; therapeutic use
Quinazolines - chemistry; therapeutic use
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, erbB-2 - antagonists & inhibitors

Associated Chemicals: Protein Kinase Inhibitors (0) ; Quinazolines (0) ; lapatinib (0) ; Receptor, Epidermal Growth Factor (EC 2.7.1.112) ; Receptor, erbB-2 (EC 2.7.1.112)

These are the highest related articles currently in the database:

See 100+ related articles.